Response to vecuronium in a patient with facioscapulohumeral muscular dystrophy.
Increased sensitivity to vecuronium has been noted in patients with Duchenne muscular dystrophy. We report the response to vecuronium in a patient with facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant disorder with an incidence of 10-20 cases per million. In this patient, sensitivity to an initial dose of vecuronium (0.02 + 0.08 mg kg-1) was normal, but recovery was faster and the effect of incremental doses of vecuronium (0.02 mg kg-1) was less than expected. Onset time and 25% recovery of T1/T0 after the intubating dose of vecuronium were 240 s and 22 min, respectively. Recovery index (spontaneous recovery of T1/T0 from 25% to 75%) was 9 min.
Nitahara
K
K
Department of Anesthesiology, School of Medicine, Fukuoka University, Japan.
Sakuragi
T
T
Matsuyama
M
M
Dan
K
K
D000328:Adult; D006801:Humans; D008297:Male; D020391:Muscular Dystrophy, Facioscapulohumeral / Q000503:physiopathology*; D019148:Neuromuscular Blockade; D009469:Neuromuscular Junction / Q000187:drug effects*; D003473:Neuromuscular Nondepolarizing Agents / Q000494:pharmacology*; D014673:Vecuronium Bromide / Q000494:pharmacology*
D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide